Document Detail

Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
MedLine Citation:
PMID:  15765299     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The tyrosine kinase inhibitor imatinib has been introduced into the treatment of gastrointestinal stromal tumors (GIST). Here we report our results of prolonged treatment in comparison to a similar group of GIST patients who had died before imatinib became available. METHODS: Fourteen patients with recurrent or metastatic GIST were treated with imatinib. Clinical data and tumor samples of ten patients from the pre-imatinib era were available for comparison. Comparative genomic hybridisation (CGH) was performed on tumors to identify changes that may predict response to treatment. RESULTS: Fourteen patients were treated, mean treatment time 22.3 months (1 non-response, 2 progression after initial response, 2 stable diseases, 8 partial responses, 1 complete response). Adverse side effects were mild in general. Survival was higher in the treated group (41.1 months vs. 34.8 months in the historical group). Eleven treated patients are alive. CGH analysis showed comparable numbers of chromosomal aberations in both groups. CONCLUSION: Prolonged treatment with imatinib is safe and effective in patients with recurrent or metastatic GIST.
C G Schindler; T Armbrust; B Gunawan; C Langer; L Füzesi; G Ramadori
Related Documents :
24854989 - How i manage mantle cell lymphoma.
15817679 - Early molecular response to posttransplantation imatinib determines outcome in mrd+ phi...
12115389 - Chronic myelogenous leukemia in t cell lymphoid blastic phase achieving durable complet...
23866799 - Surgical treatment and prognosis of thymic squamous cell carcinoma: a retrospective ana...
14670929 - The prognostic impact of autologous stem cell transplantation in patients with chronic ...
17340589 - Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction ...
12225639 - Relationship between tumor burden and serum thyroglobulin level in patients with papill...
17667529 - Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-tra...
24854989 - How i manage mantle cell lymphoma.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Zeitschrift für Gastroenterologie     Volume:  43     ISSN:  0044-2771     ISO Abbreviation:  Z Gastroenterol     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-03-14     Completed Date:  2005-05-09     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0033370     Medline TA:  Z Gastroenterol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  267-73     Citation Subset:  IM    
Department of Gastroenterology and Endocrinology, Georg August University, Göttingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use*
Chromosome Aberrations
DNA, Neoplasm / genetics
Gastrointestinal Stromal Tumors / diagnosis,  drug therapy*,  genetics,  mortality
Liver Neoplasms / radiography,  secondary
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Nucleic Acid Hybridization
Piperazines / administration & dosage,  adverse effects,  therapeutic use*
Protein Kinase Inhibitors / administration & dosage,  adverse effects,  therapeutic use*
Pyrimidines / administration & dosage,  adverse effects,  therapeutic use*
Retrospective Studies
Risk Factors
Time Factors
Tomography, X-Ray Computed
Reg. No./Substance:
0/Antineoplastic Agents; 0/DNA, Neoplasm; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Surgical strategies for the prevention of gastrointestinal tumours
Next Document:  Symptoms in patients with adenocarcinoma of the esophagus